Antiphospholipid antibodies and the protein C pathway

Lupus

Volumn 19, Issue 4, 2010, Pages 394-399

  Urbanus, R T ^a   De Laat, B ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Activated protein C; Antiphospholipid antibodies; Antiphospholipid syndrome; Beta2 glycoprotein I

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8A; DROTRECOGIN; PHOSPHOLIPID ANTIBODY; PROTEIN ANTIBODY; PROTEIN C; PROTEIN S; PROTHROMBIN; PROTHROMBIN ANTIBODY; THROMBIN; THROMBOMODULIN;

ACTIVATED PROTEIN C RESISTANCE; ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; CELL PROTECTION; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; IMMUNOASSAY; IMMUNOPATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SEPSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BLOOD COAGULATION; HEMOSTASIS; HUMANS; PROTEIN C; PROTEIN S; THROMBIN;

EID: 77951250723     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309360841     Document Type: Review

References (57)

1. Palomo I., Segovia F., Ortega C., Pierangeli S. Antiphospholipid syndrome: a comprehensive review of a complex and multisystemic disease. Clin Exp Rheumatol 2009 ; 27: 668-677.
2. Cervera R., Piette JC, Font J., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002 ; 46: 1019-1027. (Pubitemid 34303815)
3. Miyakis S., Lockshin MD, Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006 ; 4: 295-306.
4. Amengual O., Atsumi T., Koike T. Antiprothombin antibodies and the diagnosis of antiphospholipid syndrome. Clin Immunol 2004 ; 112: 144-149. (Pubitemid 38881479)
5. Nojima J., Kuratsune H., Suehisa E., et al. Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clin Chem 2001 ; 47: 1008-1015. (Pubitemid 32493585)
6. Nojima J., Iwatani Y., Ichihara K., et al. Acquired activated protein C resistance is associated with IgG antibodies to protein S in patients with systemic lupus erythematosus. Thromb Res 2009 ; 124: 127-131.
7. Giannakopoulos B., Passam F., Rahgozar S., Krilis SA Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 2007 ; 109: 422-430. (Pubitemid 46105935)
8. Charakida M., Besler C., Batuca JR, et al. Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA 2009 ; 302: 1210-1217.
9. Cuadrado MJ, Buendia P., Velasco F., et al. Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome. J Thromb Haemost 2006 ; 4: 2461-2469. (Pubitemid 44575442)
10. Urbanus RT, Derksen RH, de Groot PG Platelets and the antiphospholipid syndrome. Lupus 2008 ; 17: 888-894.
11. Rahgozar S., Yang Q., Giannakopoulos B., et al. Beta2-glycoprotein I binds thrombin via exosite I and exosite II: anti-beta2-glycoprotein I antibodies potentiate the inhibitory effect of beta2-glycoprotein I on thrombin-mediated factor XIa generation. Arthritis Rheum 2007 ; 56: 605-613. (Pubitemid 46271986)
12. Rand JH, Wu XX, Andree HA, et al. Pregnancy loss in the antiphospholipid-antibody syndrome-a possible thrombogenic mechanism. N Engl J Med 1997 ; 337: 154-160.
13. Wahl D., Membre A., Perret-Guillaume C., Regnault V., Lecompte T. Mechanisms of antiphospholipid-induced thrombosis: effects on the protein C system. Curr Rheumatol Rep 2009 ; 11: 77-81.
14. Cariou R., Tobelem G., Soria C., Caen J. Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. N Engl J Med 1986 ; 314: 1193-1194. (Pubitemid 16138675)
15. Butenas S., Orfeo T., Mann KG Tissue factor in coagulation: Which ? Where? When? Arterioscler Thromb Vasc Biol 2009 ; 29: 1989-1996.
16. di Cera E. Thrombin as procoagulant and anticoagulant. J Thromb Haemost 2007 ; 5 (Suppl 1). 196-202. (Pubitemid 46958834)
17. Hanson SR, Griffin JH, Harker LA, et al. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest 1993 ; 92: 2003-2012.
18. Dahlback B., Villoutreix BO The anticoagulant protein C pathway. FEBS Lett 2005 ; 579: 3310-3316. (Pubitemid 40804679)
19. Norstrom EA, Tran S., Steen M., Dahlback B. Effects of factor Xa and protein S on the individual activated protein C-mediated cleavages of coagulation factor Va. J Biol Chem 2006 ; 281: 31486-31494. (Pubitemid 46041413)
20. Shen L., Dahlback B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994 ; 269: 18735-18738. (Pubitemid 24226180)
21. Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. The impact of the fibrinolytic system on the risk of venous and arterial thrombosis. Semin Thromb Hemost 2009 ; 35: 468-477.
22. Vandenbroucke JP, Koster T., Briet E., et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994 ; 344: 1453-1457. (Pubitemid 24351698)
23. Reiner AP, Siscovick DS, Rosendaal FR Hemostatic risk factors and arterial thrombotic disease. Thromb Haemost 2001 ; 85: 584-595. (Pubitemid 32293691)
24. Bertina RM, Koeleman BP, Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994 ; 369: 64-67. (Pubitemid 24144355)
25. Mosnier LO, Yang XV, Griffin JH Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. J Biol Chem 2007 ; 282: 33022-33033.
26. Mosnier LO, Zlokovic BV, Griffin JH The cytoprotective protein C pathway. Blood 2007 ; 109: 3161-3172.
27. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001 ; 344: 699-709. (Pubitemid 32204987)
28. Brouwer JL, Bijl M., Veeger NJ, Kluin-Nelemans HC, van der Meer J. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 2004 ; 104: 143-148. (Pubitemid 38879850)
29. Liestol S., Sandset PM, Mowinckel MC, Wisloff F. Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants. J Thromb Haemost 2007 ; 5: 2204-2210. (Pubitemid 47617872)
30. Nojima J., Kuratsune H., Suehisa E., Iwatani Y., Kanakura Y. Acquired activated protein C resistance associated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism. Clin Chem 2005 ; 51: 545-552. (Pubitemid 40300230)
31. Galli M., Luciani D., Bertolini G., Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003 ; 102: 2717-2723. (Pubitemid 37248837)
32. Galli M., Luciani D., Bertolini G., Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003 ; 101: 1827-1832. (Pubitemid 36237580)
33. Marciniak E., Romond EH Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989 ; 74: 2426-2432. (Pubitemid 19286462)
34. Galli M., Willems GM, Rosing J., et al. Anti-prothrombin IgG from patients with anti-phospholipid antibodies inhibits the inactivation of factor Va by activated protein C. Br J Haematol 2005 ; 129: 240-247. (Pubitemid 40562445)
35. Membre A., Wahl D., Latger-Cannard V., et al. The effect of platelet activation on the hypercoagulability induced by murine monoclonal antiphospholipid antibodies. Haematologica 2008 ; 93: 566-573. (Pubitemid 351536385)
36. Galli M., Ruggeri L., Barbui T. Differential effects of anti-beta2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. Blood 1998 ; 91: 1999-2004. (Pubitemid 28185500)
37. Izumi T., Pound ML, Su Z., Iverson GM, Ortel TL Anti-beta(2)-glycoprotein I antibody-mediated inhibition of activated protein C requires binding of beta(2)-glycoprotein I to phospholipids. Thromb Haemost 2002 ; 88: 620-626. (Pubitemid 35174004)
38. Safa O., Esmon CT, Esmon NL Inhibition of APC anticoagulant activity on oxidized phospholipid by anti-{beta}2-glycoprotein I monoclonal antibodies. Blood 2005 ; 106: 1629-1635. (Pubitemid 41208575)
39. Smirnov MD, Triplett DT, Comp PC, Esmon NL, Esmon CT On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 1995 ; 95: 309-316.
40. Safa O., Hensley K., Smirnov MD, Esmon CT, Esmon NL Lipid oxidation enhances the function of activated protein C. J Biol Chem 2001 ; 276: 1829-1836. (Pubitemid 32109657)
41. Smirnov MD, Esmon CT Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem 1994 ; 269: 816-819.
42. de Laat B., Eckmann CM, van Schagen M., et al. Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C. Blood Coagul Fibrinolysis 2008 ; 19: 757-764.
43. Crowther MA, Johnston M., Weitz J., Ginsberg JS Free protein S deficiency may be found in patients with antiphospholipid antibodies who do not have systemic lupus erythematosus. Thromb Haemost 1996 ; 76: 689-691. (Pubitemid 26388170)
44. Rossetto V., Spiezia L., Franz F., et al. The role of antiphospholipid antibodies toward the protein C/protein S system in venous thromboembolic disease. Am J Hematol 2009 ; 84: 594-596.
45. Lin WS, Chen PC, Yang CD, et al. Some antiphospholipid antibodies recognize conformational epitopes shared by beta2-glycoprotein I and the homologous catalytic domains of several serine proteases. Arthritis Rheum 2007 ; 56: 1638-1647.
46. Graham A., Ford I., Morrison R., et al. Anti-endothelial antibodies interfere in apoptotic cell clearance and promote thrombosis in patients with antiphospholipid syndrome. J Immunol 2009 ; 182: 1756-1762.
47. Patterson AM, Ford I., Graham A., Booth NA, Greaves M. The influence of anti-endothelial/antiphospholipid antibodies on fibrin formation and lysis on endothelial cells. Br J Haematol 2006 ; 133: 323-330.
48. Carson CW, Comp PC, Rezaie AR, Esmon NL, Esmon CT Antibodies to thrombomodulin are found in patients with lupus anticoagulant and unexplained thrombosis. J Rheumatol 2000 ; 27: 384-390.
49. Oosting JD, Preissner KT, Derksen RH, de Groot PG Autoantibodies directed against the epidermal growth factor-like domains of thrombomodulin inhibit protein C activation in vitro. Br J Haematol 1993 ; 85: 761-768.
50. Fleck RA, Rapaport SI, Rao LV Anti-prothrombin antibodies and the lupus anticoagulant. Blood 1988 ; 72: 512-519.
51. Simmelink MJ, Fernandez JA, Derksen RH, Griffin JH, de Groot PG Low levels of activated protein C in patients with systemic lupus erythematosus do not relate to lupus anticoagulants but to low levels of factor II. Br J Haematol 2002 ; 117: 676-684.
52. White TC, Berny MA, Tucker EI, et al. Protein C supports platelet binding and activation under flow: role of glycoprotein Ib and apolipoprotein E receptor 2. J Thromb Haemost 2008 ; 6: 995-1002.
53. Sacre SM, Stannard AK, Owen JS Apolipoprotein E (apoE) iso-forms differentially induce nitric oxide production in endothelial cells. FEBS Lett 2003 ; 540: 181-187.
54. Yang XV, Banerjee Y., Fernandez JA, et al. Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. Proc Natl Acad Sci U S A 2009 ; 106: 274-279.
55. Riddell DR, Vinogradov DV, Stannard AK, Chadwick N., Owen JS Identification and characterization of LRP8 (apoER2) in human blood platelets. J Lipid Res 1999 ; 40: 1925-1930. (Pubitemid 29477264)
56. Lutters BC, Derksen RH, Tekelenburg WL, et al. Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2ĝ€2. J Biol Chem 2003 ; 278: 33831-33838.
57. Hemker HC, Al Dieri R., de Smedt E., Beguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 2006 ; 96: 553-561. (Pubitemid 44782533)